Key Takeaways
Lilly is hoping to build brand awareness of Mounjaro and Zepbound by launching DTC advertising.
The drugs generated more than $4bn in revenue in the third quarter, but sales growth plateaued in the quarter versus the prior quarter, surprising investors.
Softer than expected sales were driven by inventory and distribution issues, and were not related to patient demand or supply constraints, Lilly said.
With the supply of Lilly’s diabetes and obesity medicines Mounjaro and Zepbound stabilized, the company is planning to initiate “demand stimulating” activities for the two tirzepatide
“What we are doing right now is that we are investing heavily in our DTC effort,” Lilly USA president Patrik Jonsson said during the company’s
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?